Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 19;29(7):5084-5090.
doi: 10.3390/curroncol29070402.

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center

Alessandro Rizzo  1 , Riccardo Carloni  2   3 , Giorgio Frega  4 , Andrea Palloni  2   3 , Alessandro Di Federico  2   3 , Angela Dalia Ricci  5 , Raffaele De Luca  6 , Simona Tavolari  2 , Giovanni Brandi  2   3
Affiliations

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center

Alessandro Rizzo et al. Curr Oncol. .

Abstract

Aim: The aim of this research was to assess the impact of an intensive follow-up program on BTC patients who had received surgery with curative intent at a tertiary referral hospital.

Methods: BTC patients were followed-up every three months during the first two years after their first surgery and every six months from the third to the fifth post-operative year.

Results: A total of 278 BTC patients who received R0/R1 surgery were included. A total of 17.7% of patients underwent a second surgery following disease relapse, and none of these patients experienced additional disease relapse.

Conclusions: An intensive follow-up after surgical resection may help in the early identification of disease relapse, leading to early treatment and prolonged survival in selected cases.

Keywords: biliary tract cancer; cholangiocarcinoma; follow-up; recurrence; surveillance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The study flow chart of the included patients.
Figure 2
Figure 2
Overall survival (OS) and disease-free survival (DFS) in R0 (blue) and R1 (green) patients.
See this image and copyright information in PMC

References

    1. Rizvi S., Gores G.J. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145:1215–1229. doi: 10.1053/j.gastro.2013.10.013. - DOI - PMC - PubMed
    1. Rizvi S., Khan S.A., Hallemeier C.L., Kelley R.K., Gores G.J. Cholangiocarcinoma—Evolving concepts and therapeutic strategies. Nat. Rev. Clin. Oncol. 2018;15:95–111. doi: 10.1038/nrclinonc.2017.157. - DOI - PMC - PubMed
    1. Forner A., Vidili G., Rengo M., Bujanda L., Ponz-Sarvisé M., Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39((Suppl. S1)):98–107. doi: 10.1111/liv.14086. - DOI - PubMed
    1. Nooijen L.E., Banales J.M., de Boer M.T., Braconi C., Folseraas T., Forner A., Holowko W., Hoogwater F.J.H., Klümpen H.J., Groot Koerkamp B., et al. Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry. Cancers. 2022;14:2389. doi: 10.3390/cancers14102389. - DOI - PMC - PubMed
    1. Banales J.M., Marin J.J.G., Lamarca A., Rodrigues P.M., Khan S.A., Roberts L.R., Cardinale V., Carpino G., Andersen J.B., Braconi C., et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 2020;17:557–588. doi: 10.1038/s41575-020-0310-z. - DOI - PMC - PubMed

LinkOut - more resources